Advertisement

Phase II study of personalized cancer vaccine in CRC shows positive preliminary PFS and long-term ctDNA data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The ongoing, signal-seeking phase II portion of the phase II/III study evaluating Granite, a personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer, produced positive preliminary data. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Advertisement
Advertisement